Tymlos (abaloparatide-SC) is a medication used to treat postmenopausal women with osteoporosis. It is an injectable medication that helps to reduce the risk of fractures in these women. While the drug has been approved by the FDA, it has been found to have some unexpected side effects that physicians should be aware of. In this article, we will investigate the unexpected side effects of Tymlos and discuss the implications for physicians.
Tymlos is an injectable medication used to treat postmenopausal women with osteoporosis. It is a synthetic form of the hormone parathyroid hormone-related protein (PTHrP). It is injected subcutaneously once a day for up to two years. Tymlos helps to reduce the risk of fractures in postmenopausal women with osteoporosis.
Although Tymlos has been approved by the FDA, it has been found to have some unexpected side effects. Some of these side effects include an increase in the risk of heart attack, stroke, and death. Additionally, it has been found to increase the risk of osteosarcoma, a type of bone cancer. It has also been associated with an increased risk of hypercalcemia, which is an abnormally high level of calcium in the blood.
Given the potential side effects of Tymlos, physicians should be aware of the risks associated with the drug. It is important to discuss these potential side effects with patients before prescribing the medication. Additionally, physicians should monitor patients closely for any signs or symptoms of the side effects. If any side effects are observed, the patient should be referred to a specialist for further evaluation and treatment.
Tymlos is an injectable medication used to treat postmenopausal women with osteoporosis. While it has been approved by the FDA, it has been found to have some unexpected side effects. Physicians should be aware of these potential side effects and discuss them with their patients before prescribing the medication. Additionally, they should monitor patients closely for any signs or symptoms of the side effects. By doing so, physicians can ensure that their patients are receiving the best possible care.
1.
Sub-Q Ketamine is Safe and Very Effective for Severe Depression.
2.
Study indicates that exercise can help colon cancer survivors live as long as matched individuals
3.
Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.
4.
Can Concurrent Boost Safely Shorten Breast Cancer Radiation?
5.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
1.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
2.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
3.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
4.
Polycythemia Vera: A Historical Perspective and Contemporary Management
5.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation